Abstract
Parkinson’s disease (PD) is a complex multifactorial progressive neurodegenerative disease characterized by locomotor alteration due to the specific deterioration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc). Mounting evidence shows that human LRRK2 (hLRRK2) kinase activity is involved in oxidative stress (OS)-induced neurodegeneration, suggesting LRRK2 inhibition as a potential therapeutic target. We report that the hLRRK2 inhibitor PF-06447475 (PF-475) prolonged lifespan, increased locomotor activity, maintained DAergic neuronal integrity, and reduced lipid peroxidation (LPO) in female Drosophila melanogaster flies chronically exposed to paraquat (PQ), a redox cycling compound, compared to flies treated with vehicle only. Since LRRK2 is an evolutionary conserved kinase, the present findings reinforce the idea that either reduction or inhibition of the LRRK2 kinase might decrease OS and locomotor alterations associated with PD. Our observations highlight the importance of uncovering the function of the hLRRK2 orthologue dLrrk2 in D. melanogaster as an excellent model for pharmacological screenings.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Parkinson’s disease (PD) is a neurological condition characterized by the progressive loss of 50–70% of dopaminergic (DAergic) neurons from the substantia nigra, leading to movement alterations [1]. PD is now considered a pandemic disease [2]. Therefore, one of the major goals of PD research is to protect this group of neuronal cells from structural and functional deterioration or the dying process. Unfortunately, elucidation of the molecular mechanisms of neuronal loss or damage has been elusive until now [3, 4]. Despite this drawback, genetic and environmental factors have been postulated to play an important role in the development of PD, resulting in oxidative stress (OS), mitochondrial damage, and neuronal loss [5]. Although PD cases are mainly sporadic, about 10% of the cases have a familial origin. The most common genetic form associated with autosomal dominant familiar cases has been linked to the leucine-rich repeat kinase 2 (LRRK2) gene [6, 7]. This gene spans a 144-kb genomic region, with 51 exons encoding a large protein of 2,527 amino acids (aa) with multiple functional domains, including an ankyrin repeat region, a leucine-rich repeat domain, a kinase domain, a RAS domain, a Ras-of-complex-GTPase domain, and a WD40 motif [8]. Although the normal biological function of LRRK2 is not yet fully established, this kinase has been involved in cell survival, OS, and mitochondrial dynamics [9]. Indeed, LRRK2 kinase has been found to be responsible for OS-induced neurotoxicity [10]. In line with these findings, our laboratory group has demonstrated that inhibitor LRRK2, PF-06447475 (referred to here as PF-475; (3-[4-(Morpholin-4-yl)-7 H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile) [11], protected nerve-like differentiated cells against OS-induced apoptosis [12]. However, no data are available to establish the definitive role played by LRRK2 in OS-stimuli in vivo.
Paraquat dication (PQ2+) is chemically named 1-methyl-4-(1-methylpyridin-1-ium-4-yl) pyridin-1-ium, an organic cation that consists of 4,4’-bipyridine bearing two N-methyl substituents located at the 1- and 1’-positions (PubChem Compound CID: 15,939). Despite being a non-selective contact herbicide and highly toxic compound [13], PQ2 + is today among the most used herbicides in the world (e.g., Global Paraquat Market, 2024; https://reports.valuates.com/market-reports/QYRE-Auto-9X753/global-paraquat). Unfortunately, exposure to PQ2 + has been associated with the development of PD (e.g., [14, 15]). As a neurotoxin, PQ2 + works as a redox cycling compound [16]. PQ2 + is reduced enzymatically, mainly by NADH: ubiquinone oxidoreductase (complex I), to form the paraquat monocation (PQ·+), which is then reoxidized in the presence of dioxygen (O2) with subsequent production of superoxide anion radical (O2.−). Dismutation of this last molecule generates reactive oxygen species (ROS), leading to several cellular and molecular deleterious events, including oxidative stress (OS), mitochondria dysfunction, alteration in dopamine metabolism, and lipid peroxidation (LPO) [17, 18]. Given those well-characterized features, PQ2 + has been widely used in vivo to create a variety of PD pathological features [19].
Drosophila melanogaster (referred to here as D. melanogaster or Drosophila) is one of the most widely used experimental organisms for neurodegenerative disorders [20]. Specifically, the fly provides an excellent toolkit for the modeling of environmental and genetic aspects of PD [21,22,23]. Indeed, D. melanogaster reproduces many features of the disease, such as loss of DAergic neurons, reduced movement, mitochondrial abnormalities, LPO, and OS [24,25,26]. Human LRRK2 (hLRRK2) kinase is a highly conserved protein at a structural and functional level across species [27]. D. melanogaster has a single orthologue, dLrrk2, and the kinase domain is 31% identical and 52% similar between dLrrk2 and hLRRK2 [28]. Interestingly, studies have shown that genetic ablation of dLrrk2 in Drosophila [29, 30] or pharmacological inhibition in rats and worms [31, 32] provide resistance to OS-stimuli. Despite these advances, it is not yet established whether pharmacological inhibition offers the most effective and promising approach to PD management. Since Drosophila presents a high percentage identity and similarity of disease-related genetic variants (approximately 75%; [33]) and has deep homology with brain structures involved in PD neuropathology [34, 35], the fly might be an excellent model organism for drug screening [36].
The aim of the present investigation was to assess the effect of the hLRRK2 kinase inhibitor PF-475 in female D. melanogaster flies (w[1118]). To this end, flies were chronically exposed to PQ for 15 days in the presence or absence of the inhibitor PF-475 to evaluate lifespan, locomotor activity, integrity of DAergic neurons in terms of TH expression level, and lipid peroxidation (LPO), as indicative of OS. Our findings suggest that dLrrk2 (or hLRRK2) work as regulator of OS and that their action could be blocked by specific inhibitor LRRK2 PF-475. The high similarity between hLRRK2 and dLrrk2 highlights the importance of uncovering the function of the LRRK2 orthologue dLrrk2 in Drosophila as an invaluable model for pharmacological screenings.
Materials and methods
Fly Stock and Culture
Stock vials of Drosophila melanogaster were raised at 25 °C on a 12-hour light/dark cycle in bottles containing Nutri-FlyTM (Flystuff-Genesee Scientific) fly food medium. Propionic acid was added to prevent fungal growth (Merck-Schuchardt OHG D-85,662, Hohenbrunn, Germany). Unless specified otherwise, other reagents were purchased from Sigma (St. Louis, MO, USA). Given that female flies appeared more sensitive to PQ intoxication than males [37], wild type (WT) (Bloomington Drosophila Stock Center (BDSC) #3605, w[1118]) and TH > Lrrk2-RNAi female flies were used for experiments. Directed suppression of dLrrk2 related transgenes was achieved using the Gal4 > UAS system, with line UAS-Lrrk-RNAi (BSC #35,249: y[1]sc[⁄]v[1]; P{y[+ t7.7]v[+ t1.8] = TRiP.GL00136}attP2/TM3,Sb[1]) and TH-Gal4 ((BSC) #8848: w[⁄]; P{w[+ mC] = ple-GAL4.F}3). The sample size was calculated by power analysis according to the formulas: sample size = 2 (Zα /2 + Zβ) 2 × P(1-P)/ (p1 -p2) 2, Zα /2 = Z0.025 = 1.96 (from Z table) at a type I error of 5%; Zβ = Z0.20 = 0.842 (from Z table) at 80% power; p1-p2 = difference in proportion of events in two groups = − 0.4 Previous studies in our group suggested that if PQ (1 mM) is given for 5 days orally to flies, 50% of them will die within this period, hence survival is 50% (0.5 proportion). If PF-475 increases survival to 90% (0.9 proportions), then these findings can be considered significant. Effect size = 0.5–0.9 = − 0.4). Pooled prevalence = 0.5 + 0.9/2 = 0.7. At 5% significance level and 80% power, the sample size will be 20.60 flies (~ 21 flies) per group. This value, if adjusted for 30% attrition, will be 30 flies [38]. To increase statistical power, we thus used n = 60 flies per group for protection assays.
Experimental Procedures
Protection Assay
A protection assay was performed on virgin 2- to 3-day-old female flies collected overnight and kept on regular food medium. Subsequently, 60 separated adult female flies were starved in empty vials for 3 h at 25 °C. Then, groups of six flies were placed in ten vials containing a filter paper (Bio Rad Mini Trans-Blot 1,703,932) saturated with 1% glucose (1G, 55.5 mM glucose) in distilled water (dW) for 24 h. After this time, flies were starved in empty vials for 3 h at 25 °C and transferred to vials with a filter paper saturated with 200 µl paraquat (PQ 1 mM, MP Biomedicals cat 02195323) and/or hLRRK2 selective inhibitor PF-475 at 0.05, 0.075, and 0.1 µM (Sigma cat PZ0248) in 1G for 15 days. The PQ feeding schedule was adjusted according to the protection assay. Red food dye (8 µl/1 ml) (Red food color McCormick) was added to ensure homogeneity and food intake. Living flies were counted daily.
Locomotion Assay
The movement deficit assay was performed on treated flies, according to Ortega-Arellano et al. [39]. Briefly, treated flies were placed in empty plastic vials. After a 10-minute rest period, the flies were tapped to the bottom of the vials, and the number of flies able to climb 5 cm in 6 s was recorded at each interval of time. The assays were repeated three times at 1-minute intervals. For each experiment, a climbing percent (%) was calculated as ½ [(ntot + ntop - nbot)/ntot] x 100. Data were shown as a mean ± standard deviation of the mean (SD). The Chi Square (c2) statistic was performed to compare proportions of percentages between independent groups. Differences were considered statistically significant at p < 0.05.
Survival Test
Flies were treated chronically with paraquat (PQ; 1 mM, MP Biomedicals cat 02195323) and the selective inhibitor PF-475 (0.05, 0.075, and 0.1 mM, Sigma cat PZ0248) as described above for 15 days. Live flies were counted in groups of six per vial daily. Sixty flies per treatment were used. Survival curves were plotted using the Kaplan-Meier estimator. The statistical significance was calculated using the log rank test within the portable IBM SPSS Statistics 22 package program. The null hypothesis in all survival assays was that the exposure of PQ and/or PF-475 to female Drosophila made no difference in the survival of the flies in the absence of those reagents. Differences were considered statistically significant at p < 0.05.
Western Blotting Analysis
Adult fly heads were homogenized at 4 °C in a lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin with protease inhibitor PFMS 1 mM). Samples were placed at − 80 °C for 5 min, centrifuged for 15 min × 13,000 rpm in a cold microcentrifuge, and supernatants were recovered and stored at − 80 °C. The resulting homogenate was subjected to BCA protein assays to ensure equal protein loading, resolved on 8–12% SDS/PAGE Bis-Tris gels, and transferred onto Hybond ECL 0.45 μm Nitrocellulose membranes (GE Healthcare Life Sciences). The membranes were blocked in TBS (pH 7.4, 10 mM Tris-HCl, 150 mM NaCl, 0.1%) containing 5% non-fat milk. Primary antibodies: anti-dLrrk2 (Sigma Aldrich SAB1300356; 1:200 dilution), anti-TH (Millipore ab112; 1:5000 dilution), and anti-actin (Abcam Inc. ab50412; 1:5000 dilution) were incubated overnight in TBS-T (ph 7.4, 10 mM Tris-HCl 150 mM, NaCl 0.1%, Tween 20 0.01%) containing 1.5% non-fat milk. IRDye 800CW Donkey anti-goat or anti-rabbit (LI-COR Biosciences; 1:10,000). Proteins were detected by the Odyssey infrared imaging system (LICOR Biosciences). The WB analysis was assessed (protein/actin ratio (arbitrary units)) three times in independent experiments.
Lipid Peroxidation (LPO) Assay
Quantification of lipid peroxidation involving TBARS (thiobarbituric acid reactive substance) was performed according [40]. Briefly, 30 heads (approx. 30 mg) from untreated or PQ (1 mM) treated flies with or without PF-475 were homogenized in a 0.6 mL solution containing 50 mM sodium phosphate buffer, pH 6.0, and 10% trichloroacetic acid (TCA). Then, samples were centrifuged at 10,000 rpm for 10 min. The supernatant was divided into two aliquots. The first supernatant (0.3 mL) was mixed with 0.1 mL of 0.1 M EDTA and 0.6 mL of a solution containing 1% thiobarbituric acid in 0.05 M NaOH, and then incubated at 100 ºC for 15 min. The second aliquot (0.3 mL) was mixed with 0.7 mL of H2O and incubated under the same conditions as described above. This sample was used as an internal absorbance control to avoid artifacts in the LPO measurement. After cooling on ice, the samples were centrifuged at 10,000 rpm for 1 min. The malondialdehyde (MDA) product was measured at 535 nm. The molar absorptivity of MDA (1.56 × 105 M− 1 cm− 1) was used to express lipid peroxidation levels as MDA (nMol per mg of fly heads). To compare the differences between two or more groups, a one-way ANOVA followed by the Bonferroni post hoc comparison calculated with SPSS 25 software was performed. Differences were considered statistically significant at p < 0.05.
Molecular Docking
We used X-ray crystal structure of hLRRK2 (protein data bank code: 7LI4) and dLrrk2 (code AF-A0A0B4KHT3, created with Alphafold, https://alphafold.ebi.ac.uk/) for molecular docking experiments. The blind molecular docking was performed with CB-Dock version 2 [41], a cavity detection-guided protein-ligand blind docking web server that uses Autodock Vina (version 1.1.2, Scripps Research Institute, La Jolla, USA) or FitDock: protein-ligand docking by template fitting. The SDF structure files of the tested compounds (ATP, compound CID: 5957, and PF06447475, compound CID: 72,706,840) were downloaded from PubChem (https://pubchem.ncbi.nlm.nih.gov/; available in March 2024). The molecular blind docking was performed by uploading the 3D structure PDB file of hLRRK2 and dLrrk2 into the server with the SDF file of each compound. For analysis, we selected the docking poses with the strongest Vina score or fitDock score in the catalytical pocket. The generated PDB files of the molecular docking of each compound were visualized with the CB-Dock2 interphase or through BIOVIA Discovery Studio Visualizer (https://discover.3ds.com/discovery-studio-visualizer-download; available in March 2024) and compared against the experimentally validated X-ray structures of the interaction of ATP with hLRRK2 [42].
Results
PF06447475 (PF-475) Binds with High Affinity to the ATP-Binding Pocket of the dLrrk2 Kinase in D. melanogaster
We first investigated whether PF-475 might bind to the ATP pocket of the dLrrk2 kinase in D. melanogaster, as it has previously been reported in the hLRRK2 kinase [11]. As a validation procedure, we performed an in silico molecular docking analysis using CB-Dock2, an accurate protein-ligand blind docking tool [41], to analyze the ATP-binding and PF-475-binding pockets in hLRRK2. As expected, docking analysis reveals that ATP and PF-475 are bound to hLRRK2 with high affinity, albeit with different strengths. ATP bound to the dLRRK2 pocket with an affinity of -5.8 kCal/mol (fitDock score), involving meanly 21 aa (Table 1, Suppl Fig. S1A-B), whereas PF-475 inhibitor bound to the hLRRK2 pocket with an affinity of -6.9 kCal/mol (fitDock score), involving nearly the same aa in the catalytical pocket, 17/21 (81%) (Table 1, Suppl Fig. S1C-D). Indeed, the PF-475 inhibitor shows 1.19 times higher affinity for hLRRK2 than ATP. Similarly, molecular docking analysis shows that PF-475 bound to the hLrrk2 pocket with a higher affinity score (-8.6 kcal/mol, Vina score) than ATP (-5.7 kcal/mol, fitDock score) (Table 1; Fig. 1A-D). These theoretical calculations indicated the presence of a PF-475 high affinity binding pocket in the dLrrk2 kinase (Table 1; Fig. 1E-L).
PF-06447475 Increases Lifespan and Reduces Motor Impairment in Flies Exposed to Paraquat
Previously, it has been demonstrated that PQ (1 mM) induced a significant reduction in survival and locomotor activity in TH/+ flies and such noxious effects were importantly diminished in TH > Lrrk2-RNAi/+ flies [30]. Effectively, w[1118] flies fed with PQ (1 mM) had a significantly decreased lifespan (Fig. 2A) and locomotor activity (Fig. 2B) compared to untreated flies. Noticeably, 50% of w[1118] flies exposed to PQ perished at day 5 and reduced locomotor activity at the same day, but survival and locomotor activity in flies treated with vehicle only were extended beyond day 15 (Table 2, track 1 vs. 2, Fig. 2A and B). We confirmed that TH > Lrrk2-RNAi/+ flies exposed to PQ showed a prolonged survival (Fig. 2C) and increased percentage of climbing activity (Fig. 2D). Of note, whereas 50% of TH > Lrrk2-RNAi/+ flies treated with vehicle only extended the survival and locomotor activity beyond day 15 (Table 2, track 11, Fig. 2C and D), the knockdown flies exposed to PQ perished at day 10 and reduced locomotor activity at the same day (Table 2, track 12, Fig. 2C and D).
We next evaluated the effect of PF-475 alone or in combination with PQ. We initially fed w[1118] flies with increasing concentrations of the inhibitor PF-475 (25, 50, 75, and 100 µM). As described in Table 2, PF-475 at 25–75 µM was innocuous to flies (Table 2, tracks 3–5), whereas 100 µM PF-475 significantly reduced survival and climbing activity in flies (Table 2, track 6) compared to those treated with vehicle only (Table 2, track 1). Inhibitors increased survival and locomotor performance in a concentration-dependent fashion up to 100 µM. Therefore, we selected PF-475 (75 µM) for further experiments. Indeed, flies treated with PF-475 (75 µM) and PQ (1 mM) showed a dramatic increase in life span (Fig. 2A) and climbing activity (Fig. 2B). Remarkably, PF-475 (75 µM) increased almost 2-fold survival and locomotor activity, i.e., 50% treated flies with PQ only at day 5 versus 50% treated flies with PF-475 + PQ at day 9 (~ 45% increase). Interestingly, TH > Lrrk2-RNAi/+ flies treated with PF-475 (75 µM) only (Table 2, track 13) showed a comparable survival and climbing activity to untreated flies (Table 2, track 11), whereas PF-475 co-administered with PQ (Table 2, track 14) showed comparable survival and climbing activity to flies treated with PQ only (Table 2, track 12).
PF-06447475 Does Not Modify the Expression Level of Tyrosine Hydroxylase (TH) or dLrrk2 Protein in Wild-Type Flies Exposed to Paraquat
We wanted to evaluate whether inhibitor PF-475 affected the expression of enzyme TH or dLrrk2 kinase in the absence or presence of PQ. Western blot analysis (Fig. 3A) revealed no statistically significant differences in the expression levels of TH or dLrrk2 (Fig. 3B and C) in flies treated with vehicle only (Fig. 3A, track 1), treated with PQ only (Fig. 3A, track 2), with inhibitor only (Fig. 3A, track 3), or flies treated with both inhibitor and PQ (Fig. 3A, track 4).
LRRK2 Inhibitor PF-06447475 Reduced the Lipid Peroxidation (LPO) Index in Flies Exposed to Paraquat
The above observations prompted us to assess whether PF-475 could reduce PQ-induced OS in flies. As shown in Fig. 4 and Table 3, WT Drosophila (w[1118]) flies exposed to PQ produced a statistically increase (9-fold) in MDA compared to flies treated with vehicle only (Table 3, track 1 vs. 2). Remarkably, PF-475 significantly reduced the levels of MDA in flies treated with PQ to a comparable level to flies treated with inhibitor alone or with vehicle only (Table 3, track 1, 3 and 4). Of note, untreated knockdown flies (Table 3, track 5) or treated with PQ (Table 3, track 6), PF-475 only (Table 3, track 7), or PQ and PF-475 (Table 3, track 8) showed similar MDA values (Fig. 4).
Discussion
Parkinson’s disease is a complex disease mainly characterized by movement disorder associated with a selective degeneration of DAergic neurons [1] believed to deteriorate by the interaction of genes (e.g., LRRK2) and environmental factors (e.g., exposure to neurotoxin PQ) [43]. However, the gene-environmental interplay in PD is not yet fully understood. Remarkably, D. melanogaster has become a simple and powerful system to model PD and understand the pathophysiology of the disorder [44]. Here, we confirmed that Drosophila flies chronically exposed to PQ induce a shortage of life span, promote significant high levels of MDA as an indication of LPO and OS, and provoke locomotor impairment as an indication of functional degeneration of DAergic neurons [26, 30, 45]. Taken together, these observations suggest that PQ might be a potential neurotoxin to model Drosophila PD-like symptoms [19]. In fact, the PQ-Drosophila model has been used to interrogate potential neuroprotective compounds from natural resources (e.g., [46,47,48,49]). We also confirmed that TH > Lrrk-RNAi/+ flies treated with PQ showed an extended lifespan and locomotor activity by 100% and 125%, respectively compared to w[1118] flies treated with PQ. We conclude that reduced expression of Lrrk2 in the transgenic TH > Lrrk-RNAi/+ flies conferred resistance PQ stimuli [30].
Given that LRRK2 kinase increases the generation of ROS and causes enhanced neurotoxicity under stress stimuli in dopaminergic SN4741 cells [10] and in neuron-like cells [12], it is therefore reasonable to think that its specific inhibition might alleviate DAergic neurons from OS-induced neurodegeneration in vivo. In the present study, we show for the first time that the inhibitor LRRK2 kinase PF-06447475 (PF-475) attenuates chronic PQ-induced neurotoxicity in D. melanogaster by increasing life span, improving climbing ability, and decreasing OS. Our observations suggest that the dLrrk2 kinase modulates neurodegeneration in PD. Although the underlying mechanisms by which dLrrk2 might contribute to PQ-induced neurodegeneration are not yet fully described in the fly, we speculate that it most probably involves ROS-signaling mechanisms [12, 48, 50] and/or alterations of neurocytoskeletal proteins (e.g., [51,52,53]). Therefore, PF-475 might block dLrrk2, thereby maintaining locomotor activity, reducing OS (LPO index), and prolonging life span, indicative of normal DAergic neuronal functionality. Interestingly, neither PQ alone nor in combination with PF-475 affected the expression levels of TH or dLrrk2. Taken together, these results imply that PF-475 is capable of protecting Drosophila against PQ-induced neurodegeneration [30, 45]. These observations suggest that switching off hLRRK2 and dLrrk2 by specific PF-06447475 might be an achievable therapeutic approach in sporadic as well as familial PD.
PF-475 is a second-generation LRRK2 inhibitor with high potency, selectivity, and good blood-brain barrier (BBB) permeability properties in mice and rats [11]. Recent cryo-electron microscopy (cryoEM) analysis of the hLRRK2 protein (resolution 3.10 Armstrong) has provided the means to delve into the structure-function interaction between hLRRK2, its natural ligand ATP, and the inhibitor PF-475 [8]. By using in silico molecular docking analysis, we found that PF-475 binds to hLRRK2 (PDB: 7LI4) with a higher bonding affinity than ATP (1.189-fold increased), involving 16/21 (76%) identical aa residues in the binding pocket of the kinase (Table 1). Interestingly, by using mammalian STE20-like protein kinase 3 (MST3, residues 1-303; NP_001027467; PDB ID: 4U8Z; ATP-binding site residue shows 73% similarity to human LRRK2) as a surrogate crystallographic system for hLRRK2, Henderson and co-workers [11] determined ASP1887, VAL1893, LYS1906, GLU1948, and ALA1950 as important aa residues in the interaction with PF-475. Similarly, we found identical aa interacting in the pocket of hLRRK2 and the inhibitor (Table 1, Suppl. Fig. s2). Interestingly, a BLAST analysis revealed a 30% identity and 48% similarity between the full length in aa residues of protein dLrrk2 (Uniprot Q9VDJ9|LRRK2_DROME, length 2,445) and hLRRK2 (Uniprot Q5S007|LRRK2_HUMAN, length 2,527). Moreover, a similar BLAST analysis showed a 34% identity and 51% similarity between the kinase domain aa residues of dLrrk2 (Uniprot Q9VDJ9, location 1,728-2,034) and hLRRK2 (Uniprot Q5S007, location 1,879-2,138), including an identical matched sequence at the ATP binding site (dLrrk2: 1911KIADYGI1917; hLRRK2: 2015KIADYGI2021) according to software tool FIMO (Find Individual Motif Occurrences [54]. Since PF-475 binds to the ATP pocket in the kinase domain through a DXG motif [55, 56], it is reasonable to think that PF-475 operates as an effective blocker of dLrrk2 through a similar molecular interaction with the human DXG motif. Not surprisingly, PF-475 bound to the binding pocket of dLrrk2 with a higher affinity than ATP (-5.7 vs. -8.6 fitDock score). Taken together, our findings suggest that both hLRRK2 and dLrrk2 are biologically and functionally equivalent. Therefore, the use of Drosophila as an invaluable surrogate in vivo PD model to investigate other potential LRRK2 inhibitors either from natural products (e.g., [57]) or chemical libraries (e.g., [58]) in a simple, fast, reliable, and inexpensive manner. Provided that PF-475 (and other kinase inhibitors) interact with mammalian (hLRRK2) or invertebrate (dLrrk2) kinase in a similar molecular mechanism, we anticipate that pharmacological inhibitors might effectively inhibit LRRK2 in PD patients [59, 60]. Therefore, we anticipate that the use of flies with LRRK2 mutations associated with familial PD (e.g., G2019S, BDSC#602459) might increase the success of finding an effective inhibitor of hLRRK2 for the treatment of PD.
Previous studies have shown that reduced expression of dLrrk2 in the DAergic neurons of transgenic flies conferred PQ resistance and the absence of neurodegeneration [28,29,30]. Specifically, it has been shown that transgenic flies dramatically increased locomotor activity, reduced the lipid peroxidation (LPO) index alone or in the presence of PQ, presented an extended life span, and showed DAergic neuron integrity and/or functionality. Our present investigation shows similar observations when w[1118] flies were treated with PF-475 and PQ. As expected, PF-475 was inoperant in knockdown flies. Indeed, TH > Lrrk2-RNAi/+ flies exposed to PF-475 and PQ behave similarly as knockdown flies treated with PQ alone. Taken together, these observations suggest that both knockdown and pharmacologic models are biologically comparable and that reduced or suppressed LRRK2 expression by pharmacologic or gene LRRK2 blockage might delay or prevent motor symptoms in persons at risk of suffering Parkinsonism by impeding structural or functional impairment (= neurodegeneration) in the DAergic neurons. However, the pharmacology approach might be ideal over gene therapy for clinical trials.
Conclusion
LRRK2 is a serine-threonine kinase involved in multiple cellular processes and signaling pathways in PD [61]. Therefore, inhibition of LRRK2 kinase function is a promising therapeutic strategy for PD treatment [62]. Here, we demonstrate that the small-molecule kinase inhibitor PF-06447475 can protect Drosophila against OS-induced neurodegeneration. Since Drosophila might be biologically homologous to mammalian model organisms (e.g., mice, rats), the fly is an important resource to test and discover new therapeutic compounds. The present Drosophila-PQ model might serve as a reference assay, which, together with in silico data results from chemical libraries and/or natural compounds, offers a unique opportunity to speed up the development of novel LRRK2 inhibitors.
Data Availability
No datasets were generated or analysed during the current study.
References
Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46 suppl 1. Suppl 1S30–S33. https://doi.org/10.1016/j.parkreldis.2017.07.033
Dorsey ER, Bloem BR (2018) The Parkinson Pandemic-A call to action. JAMA Neurol 75(1):9–10. https://doi.org/10.1001/jamaneurol.2017.3299
Erekat NS (2018) Apoptosis and its Role in Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications Chap. 4
Memou A, Dimitrakopoulos L, Kedariti M, Kentros M, Lamprou A, Petropoulou-Vathi L, Valkimadi PE, Rideout HJ (2021) Defining (and blocking) neuronal death in Parkinson’s disease: does it matter what we call it? Brain Res 1771:147639. https://doi.org/10.1016/j.brainres.2021.147639
Chen C, Turnbull DM, Reeve AK (2019) Mitochondrial dysfunction in Parkinson’s Disease-cause or Consequence? Biology (Basel) 8(2):38. https://doi.org/10.3390/biology8020038
Simpson C, Vinikoor-Imler L, Nassan FL, Shirvan J, Lally C, Dam T, Maserejian N (2022) Prevalence of ten LRRK2 variants in Parkinson’s disease: a comprehensive review. Parkinsonism Relat Disord 98:103–113. https://doi.org/10.1016/j.parkreldis.2022.05.012
Ito G, Utsunomiya-Tate N (2023) Overview of the impact of pathogenic LRRK2 mutations in Parkinson’s Disease. Biomolecules 13(5):845. https://doi.org/10.3390/biom13050845
Myasnikov A, Zhu H, Hixson P, Xie B, Yu K, Pitre A, Peng J, Sun J (2021) Structural analysis of the full-length human LRRK2. Cell 184(13):3519–3527e10. https://doi.org/10.1016/j.cell.2021.05.004
Singh A, Zhi L, Zhang H (2019) LRRK2 and mitochondria: recent advances and current views. Brain Res 1702:96–104. https://doi.org/10.1016/j.brainres.2018.06.010
Heo HY, Park JM, Kim CH, Han BS, Kim KS, Seol W (2010) LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 316(4):649–656. https://doi.org/10.1016/j.yexcr.2009.09.014
Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD, Galatsis P (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 58(1):419–432. https://doi.org/10.1021/jm5014055
Mendivil-Perez M, Velez-Pardo C, Jimenez-Del-Rio M (2016) Neuroprotective effect of the LRRK2 kinase inhibitor PF-06447475 in human nerve-like differentiated cells exposed to oxidative stress stimuli: implications for Parkinson’s Disease. Neurochem Res 41(10):2675–2692. https://doi.org/10.1007/s11064-016-1982-1
Sukumar CA, Shanbhag V, Shastry AB (2019) Paraquat: the poison potion. Indian J Crit Care Med 23(Suppl 4):S263–S266. https://doi.org/10.5005/jp-journals-10071-23306
Vaccari C, El Dib R, Gomaa H, Lopes LC, de Camargo JL (2019) Paraquat and Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Toxicol Environ Health B Crit Rev 22(5–6):172–202. https://doi.org/10.1080/10937404.2019.1659197
Paul KC, Cockburn M, Gong Y, Bronstein J, Ritz B (2024) Agricultural paraquat dichloride use and Parkinson’s disease in California’s Central Valley. Int J Epidemiol 53(1):dyae004. https://doi.org/10.1093/ije/dyae004
Blanco-Ayala T, Andérica-Romero AC, Pedraza-Chaverri J (2014) New insights into antioxidant strategies against paraquat toxicity. Free Radic Res 48(6):623–640. https://doi.org/10.3109/10715762.2014.899694
See WZC, Naidu R, Tang KS (2022) Cellular and molecular events leading to Paraquat-Induced apoptosis: mechanistic insights into Parkinson’s Disease Pathophysiology. Mol Neurobiol 59(6):3353–3369. https://doi.org/10.1007/s12035-022-02799-2
Sharma P, Mittal P (2024) Paraquat (herbicide) as a cause of Parkinson’s Disease. Parkinsonism Relat Disord 119:105932. https://doi.org/10.1016/j.parkreldis.2023.105932
Thirugnanam T, Santhakumar K (2022) Chemically induced models of Parkinson’s disease. Comp Biochem Physiol C Toxicol Pharmacol 252:109213. https://doi.org/10.1016/j.cbpc.2021.109213
Liguori F, Pandey UB, Digilio FA (2023) Editorial: Drosophila as a model to study neurodegenerative diseases. Front Neurosci 17:1275253. https://doi.org/10.3389/fnins.2023.1275253
Aryal B, Lee Y (2019) Disease model organism for Parkinson disease: Drosophila melanogaster. BMB Rep 52(4):250–258. https://doi.org/10.5483/BMBRep.2019.52.4.204
Naz F, Siddique YH (2021) Drosophila melanogaster a Versatile Model of Parkinson’s Disease. CNS Neurol Disord Drug Targets 20(6):487–530. https://doi.org/10.2174/1871527320666210208125912
Rahul, Siddique YH (2022) Drosophila: a model to study the pathogenesis of Parkinson’s Disease. CNS Neurol Disord Drug Targets 21(3):259–277. https://doi.org/10.2174/1871527320666210809120621
Barone MC, Bohmann D (2013) Assessing neurodegenerative phenotypes in Drosophila dopaminergic neurons by climbing assays and whole brain immunostaining. J Vis Exp 74:e50339. https://doi.org/10.3791/50339
Hewitt VL, Whitworth AJ (2017) Mechanisms of Parkinson’s Disease: lessons from Drosophila. Curr Top Dev Biol 121:173–200. https://doi.org/10.1016/bs.ctdb.2016.07.005
Niveditha S, Ramesh SR, Shivanandappa T (2017) Paraquat-Induced Movement disorder in relation to oxidative stress-mediated neurodegeneration in the brain of Drosophila melanogaster. Neurochem Res 42(11):3310–3320. https://doi.org/10.1007/s11064-017-2373-y
Langston RG, Rudenko IN, Cookson MR (2016) The function of orthologues of the human Parkinson’s disease gene LRRK2 across species: implications for disease modelling in preclinical research. Biochem J 473(3):221–232. https://doi.org/10.1042/BJ20150985
Wang D, Tang B, Zhao G, Pan Q, Xia K, Bodmer R, Zhang Z (2008) Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3:3. https://doi.org/10.1186/1750-1326-3-3
Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27(18):2432–2443. https://doi.org/10.1038/emboj.2008.163
Quintero-Espinosa D, Jimenez-Del-Rio M, Velez-Pardo C (2017) Knockdown transgenic Lrrk Drosophila resists paraquat-induced locomotor impairment and neurodegeneration: a therapeutic strategy for Parkinson’s disease. Brain Res 1657:253–261. https://doi.org/10.1016/j.brainres.2016.12.023
Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG (2013) Kinase inhibitors arrest neurodegeneration in cell and C. Elegans models of LRRK2 toxicity. Hum Mol Genet 22(2):328–344. https://doi.org/10.1093/hmg/dds431
Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-Synuclein gene-induced neurodegeneration. J Biol Chem 290(32):19433–19444. https://doi.org/10.1074/jbc.M115.660001
Reiter LT, Potocki L, Chien S, Gribskov M, Bier E (2001) A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res 11(6):1114–1125. https://doi.org/10.1101/gr.169101
Strausfeld NJ, Hirth F (2013) Deep homology of arthropod central complex and vertebrate basal ganglia. Science 340(6129):157–161. https://doi.org/10.1126/science.1231828
Kasture AS, Hummel T, Sucic S, Freissmuth M (2018) Big lessons from tiny flies: Drosophila melanogaster as a model to explore dysfunction of dopaminergic and serotonergic Neurotransmitter systems. Int J Mol Sci 19(6):1788. https://doi.org/10.3390/ijms19061788
Su TT (2019) Drug screening in Drosophila; why, when, and when not? Wiley Interdiscip Rev Dev Biol 8(6):e346. https://doi.org/10.1002/wdev.346
Jimenez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C (2008) The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson’s disease. Neurosci Res 61(4):404–411. https://doi.org/10.1016/j.neures.2008.04.011
Charan J, Biswas T (2013) How to calculate sample size for different study designs in medical research? Indian J Psychol Med 35(2):121–126. https://doi.org/10.4103/0253-7176.116232
Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C (2017) Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: implications for autosomic recessive juvenile parkinsonism. Neurotoxicology 60:42–53. https://doi.org/10.1016/j.neuro.2017.03.002
Lavara-Culebras E, Muñoz-Soriano V, Gómez-Pastor R, Matallana E, Paricio N (2010) Effects of pharmacological agents on the lifespan phenotype of Drosophila DJ-1beta mutants. Gene 462(1–2):26–33. https://doi.org/10.1016/j.gene.2010.04.009
Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y (2022) CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res 50(W1):W159–W164. https://doi.org/10.1093/nar/gkac394
Zhu H, Hixson P, Ma W, Sun J (2024) Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM. Cell Discov 10(1):10. https://doi.org/10.1038/s41421-023-00639-8
Cannon JR, Greenamyre JT (2013) Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiol Dis 57:38–46. https://doi.org/10.1016/j.nbd.2012.06.025
Xiong Y, Yu J (2018) Modeling Parkinson’s Disease in Drosophila: what have we learned for Dominant traits? Front Neurol 9:228. https://doi.org/10.3389/fneur.2018.00228
Navarro JA, Heßner S, Yenisetti SC, Bayersdorfer F, Zhang L, Voigt A, Schneuwly S, Botella JA (2014) Analysis of dopaminergic neuronal dysfunction in genetic and toxin-induced models of Parkinson’s disease in Drosophila. J Neurochem 131(3):369–382. https://doi.org/10.1111/jnc.12818
Jahromi SR, Haddadi M, Shivanandappa T, Ramesh SR (2015) Attenuation of neuromotor deficits by natural antioxidants of Decalepis Hamiltonii in transgenic Drosophila model of Parkinson’s disease. Neuroscience 293:136–150. https://doi.org/10.1016/j.neuroscience.2015.02.048
Soares JJ, Rodrigues DT, Gonçalves MB, Lemos MC, Gallarreta MS, Bianchini MC, Gayer MC, Puntel RL, Roehrs R, Denardin ELG (2017) Paraquat exposure-induced Parkinson’s disease-like symptoms and oxidative stress in Drosophila melanogaster: neuroprotective effect of Bougainvillea glabra Choisy. Biomed Pharmacother 95:245–251. https://doi.org/10.1016/j.biopha.2017.08.073
Srivastav S, Fatima M, Mondal AC (2018) Bacopa monnieri alleviates paraquat induced toxicity in Drosophila by inhibiting jnk mediated apoptosis through improved mitochondrial function and redox stabilization. Neurochem Int 121:98–107. https://doi.org/10.1016/j.neuint.2018.10.001
Wongchum N, Dechakhamphu A (2021) Ethanol extract of Cassia siamea L. increases life span in Drosophila melanogaster. Biochem Biophys Rep 25:100925. https://doi.org/10.1016/j.bbrep.2021.100925
Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C (2013) Dmp53, basket and drICE gene knockdown and polyphenol gallic acid increase life span and locomotor activity in a Drosophila Parkinson’s disease model. Genet Mol Biol 36(4):608–615. https://doi.org/10.1590/S1415-47572013000400020
Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, Obata F (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS ONE 7(1):e30834. https://doi.org/10.1371/journal.pone.0030834
Guerreiro PS, Gerhardt E, Lopes da Fonseca T, Bähr M, Outeiro TF, Eckermann K (2016) LRRK2 promotes tau Accumulation, Aggregation and Release. Mol Neurobiol 53(5):3124–3135. https://doi.org/10.1007/s12035-015-9209-z
Bardai FH, Ordonez DG, Bailey RM, Hamm M, Lewis J, Feany MB (2018) Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. PLoS Biol 16(12):e2006265. https://doi.org/10.1371/journal.pbio.2006265
Grant CE, Bailey TL, Noble WS (2011) FIMO: scanning for occurrences of a given motif. Bioinformatics 27(7):1017–1018. https://doi.org/10.1093/bioinformatics/btr064
Liu Z, Galemmo RA Jr, Fraser KB, Moehle MS, Sen S, Volpicelli-Daley LA, DeLucas LJ, Ross LJ, Valiyaveettil J, Moukha-Chafiq O, Pathak AK, Ananthan S, Kezar H, White EL, Gupta V, Maddry JA, Suto MJ, West AB (2014) Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J Biol Chem 289(47):32937–32951. https://doi.org/10.1074/jbc.M114.602318
Schmidt SH, Knape MJ, Boassa D, Mumdey N, Kornev AP, Ellisman MH, Taylor SS, Herberg FW (2019) The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain. Proc Natl Acad Sci U S A 116(30):14979–14988. https://doi.org/10.1073/pnas.1900289116
Ivanova L, Karelson M, Dobchev DA (2018) Identification of natural compounds against neurodegenerative diseases using in Silico Techniques. Molecules 23(8):1847. https://doi.org/10.3390/molecules23081847
Sebastián-Pérez V, Martínez MJ, Gil C, Campillo NE, Martínez A, Ponzoni I (2019) QSAR Modelling to identify LRRK2 inhibitors for Parkinson’s Disease. J Integr Bioinform 16(1):20180063. https://doi.org/10.1515/jib-2018-0063
Lewis PA (2022) A step forward for LRRK2 inhibitors in Parkinson’s disease. Sci Transl Med 14:eabq7374
Azeggagh S, Berwick DC (2022) The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson’s disease: the current state of play. Br J Pharmacol 179(8):1478–1495. https://doi.org/10.1111/bph.15575
Taymans JM, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, Peter I, Rideout H, Thaler A (2023) Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis 9(1):104. https://doi.org/10.1038/s41531-023-00544-7
Wojewska DN, Kortholt A (2021) LRRK2 targeting strategies as potential treatment of Parkinson’s Disease. Biomolecules 11(8):1101. https://doi.org/10.3390/biom11081101
Yang X, Liu Y, Gan J, Xiao ZX, Cao Y (2022) FitDock: protein-ligand docking by template fitting. Brief Bioinform 23(3):bbac087. https://doi.org/10.1093/bib/bbac087
Acknowledgements
This work was supported by the “Committee for Development and Research” (Comité para el Desarrollo y la Investigación-CODI, Universidad de Antioquia-UdeA) grants (#2018-764- ES84170165) to MJ-Del-R and CV-P. DAQ-E is a doctoral student from the Neuroscience program at the Basic Biomedical Sciences Academic Corporation-UdeA. The authors would like to thank D Martinez-Perez for technical assistance (WB analysis). The authors would also like to thank the Neuroscience Research Group at the UdeA for the use of the Odyssey Infrared Imaging System.
Funding
Open Access funding provided by Colombia Consortium
Author information
Authors and Affiliations
Contributions
MJ-Del-R and CV-P conceived and designed the experiments; DAQ-E performed the experiments and wrote the first draft of paper; DAQ-E, CV-P, and MJ-Del-R analyzed the data; CV-P contributed reagents/materials/analysis tools; CV-P and MJ-Del-R wrote, edited and all approved the paper.
Corresponding authors
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Quintero-Espinosa, D.A., Jimenez-Del-Rio, M. & Velez-Pardo, C. LRRK2 Kinase Inhibitor PF-06447475 Protects Drosophila melanogaster against Paraquat-Induced Locomotor Impairment, Life Span Reduction, and Oxidative Stress. Neurochem Res 49, 2440–2452 (2024). https://doi.org/10.1007/s11064-024-04141-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-024-04141-9